Active Ingredient History
Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin’s lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Asthma (Phase 3)
Dermatitis (Phase 3)
Dermatitis, Atopic (Phase 3)
Eczema (Phase 3)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 1/Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Skin Diseases (Phase 3)
Skin Diseases, Genetic (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue